Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $13.5 million.

  • Arrowhead Pharmaceuticals' Cash from Operations rose 10921.64% to $13.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $339.3 million, marking a year-over-year increase of 16906.51%. This contributed to the annual value of $179.6 million for FY2025, which is 13879.26% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Cash from Operations stood at $13.5 million, which was up 10921.64% from $20.5 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Cash from Operations' 5-year high stood at $460.1 million during Q1 2025, with a 5-year trough of -$154.7 million in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Cash from Operations value was -$46.5 million (recorded in 2021), while the average stood at -$17.5 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Cash from Operations soared by 105658.15% in 2021, and later tumbled by 45550.85% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Cash from Operations (Quarter) stood at -$61.3 million in 2021, then fell by 23.17% to -$75.5 million in 2022, then crashed by 56.05% to -$117.8 million in 2023, then dropped by 24.13% to -$146.3 million in 2024, then soared by 109.22% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q4 2025, $20.5 million for Q3 2025, and -$154.7 million during Q2 2025.